Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Aged
Antibodies, Monoclonal, Humanized
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Disease Progression
Endometrial Neoplasms
/ drug therapy
Female
Humans
Microsatellite Instability
Middle Aged
Phenylurea Compounds
/ adverse effects
Progression-Free Survival
Quinolines
/ adverse effects
Time Factors
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 09 2020
10 09 2020
Historique:
pubmed:
14
3
2020
medline:
25
2
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors. Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORR At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with a median follow-up of 18.7 months. The ORR Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.
Identifiants
pubmed: 32167863
doi: 10.1200/JCO.19.02627
pmc: PMC7479759
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Phenylurea Compounds
0
Quinolines
0
pembrolizumab
DPT0O3T46P
lenvatinib
EE083865G2
Banques de données
ClinicalTrials.gov
['NCT02501096']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2981-2992Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
J Womens Health (Larchmt). 2019 Feb;28(2):237-243
pubmed: 30484734
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
J Clin Oncol. 2011 Jun 1;29(16):2259-65
pubmed: 21537039
Cancer Sci. 2018 Dec;109(12):3993-4002
pubmed: 30447042
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cureus. 2018 Apr 23;10(4):e2521
pubmed: 29942724
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Gynecol Oncol. 2015 Jul;138(1):18-23
pubmed: 25925990
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cancer Lett. 2013 Oct 28;340(1):97-103
pubmed: 23856031
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
PLoS One. 2019 Feb 27;14(2):e0212513
pubmed: 30811474
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2019 Oct 20;37(30):2786-2794
pubmed: 31461377
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1407-15
pubmed: 26290568
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
Cancer. 2012 May 1;118(9):2338-66
pubmed: 22460733
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
J Clin Oncol. 1996 Feb;14(2):357-61
pubmed: 8636744
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Clin Cancer Res. 2018 Dec 1;24(23):5939-5947
pubmed: 30068706
Lancet Oncol. 2019 May;20(5):711-718
pubmed: 30922731
Gynecol Oncol Res Pract. 2017 Dec 2;4:19
pubmed: 29214032
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510